RJA
PRCT icon

Raymond James & Associates’s Procept Biorobotics PRCT Stock Holding History

Raymond James & Associates’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.27M Buy
15,789
+3,494
+28% +$248K ﹤0.01% 2530
2024
Q2 		$751K Buy
12,295
+2,343
+24% +$139K ﹤0.01% 2826
2024
Q1 		$492K Buy
+9,952
New +$474K ﹤0.01% 3069

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Raymond James & Associates's PRCT Position: Q3 2024 in Review

Raymond James & Associates increased its Procept Biorobotics (PRCT) stake by 28% in Q3 2024, buying an estimated $248K and bringing the position to 15,789 shares worth $1.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2530.

Raymond James & Associates first reported a position in PRCT in Q1 2024 and has held it in 3 quarters since. 250 funds tracked by Wall St. Rank hold PRCT as of Q3 2024.

  • Raymond James & Associates held 15,789 shares of Procept Biorobotics worth $1.27M as of Q3 2024.
  • Raymond James & Associates bought 3,494 Procept Biorobotics shares in Q3 2024, an estimated $248K.
  • Procept Biorobotics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2530 holding.
  • Raymond James & Associates first reported a position in Procept Biorobotics in Q1 2024 and has held it in 3 quarters since.
  • 250 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.